Freedom Broker Has Lowered Expectations for Niagen Bioscience (NASDAQ:NAGE) Stock Price

Niagen Bioscience (NASDAQ:NAGE) had its price target decreased by stock analysts at Freedom Broker from $8.50 to $6.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Freedom Broker‘s price objective suggests a potential upside of 189.86% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the company. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Canaccord Genuity Group reduced their price target on shares of Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Friday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.50.

Niagen Bioscience Trading Down 1.9%

NAGE stock traded down $0.04 during trading on Friday, reaching $2.07. 597,674 shares of the stock were exchanged, compared to its average volume of 839,384. The firm’s 50 day moving average is $2.79 and its 200 day moving average is $3.85. The firm has a market cap of $164.85 million, a P/E ratio of 17.25 and a beta of 2.12. Niagen Bioscience has a twelve month low of $2.04 and a twelve month high of $7.28.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). The firm had revenue of $27.19 million during the quarter. Niagen Bioscience had a return on equity of 10.26% and a net margin of 8.37%. As a group, analysts predict that Niagen Bioscience will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Niagen Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAGE. SteelPeak Wealth LLC raised its position in Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock valued at $10,446,000 after buying an additional 77,306 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after acquiring an additional 761,685 shares during the last quarter. Tieton Capital Management LLC purchased a new position in Niagen Bioscience during the 2nd quarter worth $6,407,000. Renaissance Technologies LLC boosted its holdings in Niagen Bioscience by 45.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after acquiring an additional 414,725 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Niagen Bioscience by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company’s stock worth $4,723,000 after acquiring an additional 150,763 shares in the last quarter. 15.41% of the stock is owned by institutional investors.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
• Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.